Literature DB >> 15886478

Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C.

Elif Doyuk Kartal1, Hasan Colak, Ilhan Ozgunes, Gaye Usluer.   

Abstract

A 45-year-old woman with chronic hepatitis C was treated with peginterferon alpha-2b in combination with ribavirin, which activated psoriasis. In the patient, psoriasis reoccurred after being inactive for 10 years. One week after institution of therapy, she presented with plaques of psoriasis at her injection site having been administered a first dose of peginterferon alpha-2b. Psoriatic lesions of the patient worsened dramatically during therapy. Cutaneous lesions appeared at the injection sites, in the face, the scalp hair, at the back of the ears, under the breasts and armpits, and in the regions of the anus and elbows. In the second week of treatment, transaminase levels of the patient regressed to normal. Detectable hepatitis C virus RNA in the serum was eliminated at week 14 of treatment. Because of the severity of psoriatic disease activity, therapy was discontinued at the end of 14 weeks after treatment onset. This side effect of peginterferon alpha-2b plus ribavirin treatment should be kept in mind in the treatment of patients with a history of psoriasis combined with active hepatitis C. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886478     DOI: 10.1159/000085626

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

2.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

3.  Onychomycosis Case Developing during Interferon Treatment.

Authors:  Nazan Tuna; Mustafa Teoman Erdem; Oğuz Karabay
Journal:  Balkan Med J       Date:  2013-03       Impact factor: 2.021

4.  Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome.

Authors:  Ann L Truelove; Taras K Oleksyk; Sadeep Shrestha; Chloe L Thio; James J Goedert; Sharyne M Donfield; Gregory D Kirk; David L Thomas; Stephen J O'Brien; Michael W Smith
Journal:  Int J Immunogenet       Date:  2008-06       Impact factor: 1.466

Review 5.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

6.  Extensive psoriasis induced by pegylated interferon: a case report.

Authors:  Vincenzo Citro; Raffaele Fristachi; Giovanni Tarantino
Journal:  J Med Case Rep       Date:  2007-09-17

7.  Extensive psoriasis induced by pegylated interferon alfa-2a and ribavirin in the treatment of chronic hepatitis C.

Authors:  Gun-Wook Kim; Seung-Wook Jwa; Margaret Song; Hoon-Soo Kim; Byung-Soo Kim; Moon-Bum Kim; Hyun-Chang Ko
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.